2026 Deal of the Year, TechPoint Mira Awards
Recognized for BiomEdit's $18.4M Series B round, led by Elanco Animal Health.
BiomEdit / Investors
Backed by leaders in agtech, life sciences, and sustainability
BiomEdit is pioneering Programmable Veterinary Biologics™, with investors and partners who understand what it takes to bring this category to market. Our first product, CPerf LLV*, is on track for commercial launch in Q4 2026, as we continue to advance new solutions across our multi-species pipeline.
Investors
Partnerships & Grants
Launch Partners
“BiomEdit is creating a new category in animal health through Programmable Veterinary Biologics. Its differentiated platform brings together deep scientific expertise and the potential to change how the industry approaches disease prevention. We backed Aaron and the BiomEdit team early because they are building more than another product. They are creating an entirely new approach.”
Brett Wong, Partner, Anterra CapitalA new category, built for what’s next in animal health.
1
First-of-its-kind Programmable Veterinary Biologic
CPerf LLV* is the first engineered microbial biologic for poultry ever to achieve USDA conditional licensure.
2
Our Platform
Our Programmable Veterinary Biologics platform combines strain engineering, computational biology, and a microbial strain library. We engineer beneficial bacteria to perform specific biological functions, as demonstrated by CPerf LLV*. With the acquisition of Folium Science, the platform also includes CRISPR-based Guided Biotics technology that selectively targets specific bacterial populations within the microbiome, as demonstrated by BiomElix® One, approved in Brazil.
3
Foundational Patents
We have patents that protect the core delivery mechanism and the nanobody sequences behind CPerf LLV* and other programs.
4
Capital Efficiency
We have raised over $7M in non-dilutive capital to support sustainability-focused work, including high-profile grant support from the Bezos Earth Fund and the Gates Foundation.
5
Programmable Architecture
We adapt the same strain engineering across payloads, targets, species, and disease areas, spanning poultry, swine, cattle, dogs, and cats, so each new product builds on proven ground instead of starting over.
6
Durable IP Across the Full Stack
We generate protected intellectual property (IP) with every product across strain, delivery mechanism, indication, and process, compounding the platform’s competitive advantage with each release.
7
A Results-Driven Team
Our executive team has over 200 years of combined experience, over 450 publications, and a track record of inventing dozens of commercial animal health innovations.
Industry recognition for what we deliver.
Key Awards & Honors
2022 Best Start-Up in Animal Health, S&P Global Animal Health
Awarded shortly after BiomEdit's founding.
Major Grants & Funding Awards
2025 Bezos Earth Fund AI Award
Nearly $2M to develop the Rumen Digital Twin, an AI model for reducing cattle methane emissions.
2023 Bill & Melinda Gates Foundation Grant
$4.5M to advance microbiome-based methane reduction for cattle in Africa and South Asia.
How we work with partners and investors.
BiomEdit is a private venture funded biotechnology company that targets venture capital and non-dilutive grants. Venture capital typically supports advancement of the pipeline while non-dilutive grants have supported the exploration and establishment of new pipeline projects.
Let’s meet
Want to learn more about BiomEdit?
All third-party trademarks, service marks, trade names, trade dress, product names, and logos appearing on this page—including Anterra Capital, Viking Global Investors, Betagro Ventures, Elevate Ventures, Nutreco, AgriZeroNZ, Bill & Melinda Gates Foundation, Elanco, USDA, NIH, Ginkgo Bioworks, Ferment, TechPoint, and S&P Global—are the property of their respective owners. Their display on this site does not imply endorsement, sponsorship, or affiliation except as formally contracted.
*Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector